Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss CDMO Lonza, part of a drive to match capacity with pipeline requirements. The pharma group has been looking for a buyer for the plant in Vacaville, run by its Genentech subsidiary, since the middle of last year. First opened in 1998, it is said to be one of the largest in the world for biologic medicines, with more than 427,000 sq ft of space devoted to manufacturing, maintenance, laboratories, office space, and warehousing. Source: Pharmaphorum 20/3/2024